While targeted therapies are preferable to chemotherapy as first-line treatment for patients with oestrogen receptor α positive (ERα+) and HER2-positive (HER2+) metastatic BC, chemotherapy is often the initial therapeutic modality of choice for triple negative, and locally advanced or metastatic BC. Here, ERBB2 is linked to breast cancer.